Retension Pharmaceuticals gets Leerink Partners Outperform rating, $50 price target
RTSN•Leerink Partners initiated coverage of Retension Pharmaceuticals with an Outperform rating and a $50 price target.
Related News
Ero Copper Corp.: Raymond James cuts target price to C$54 from C$55
ERO•
Phinia to participate in Stephens Annual Investment Conference
PHIN•
Foremost Clean Energy forms GR and Blackwing exploration joint ventures with Denison Mines
FMST•
Cipher Digital target price cut to $19 from $30 by Rosenblatt Securities
CIFR•
Decoy Therapeutics targets second-half 2027 trial application for pan-coronavirus candidate
DCOY•